GAD1 and COVID-19: Third, the prevalence of autoimmune biomarkers such as anti-GAD (a marker of islet autoimmunity) or interferon alpha-4 antibody (an autoimmune marker recently associated with COVID-19 severity) [44] was generally very low and did not differ between COVID-associated hyperglycaemia and pre-existing diabetes.